Home Cell Therapy Sigilon Therapeutics approaches the clinic

Sigilon Therapeutics approaches the clinic

ORPHAN STATUS FOR ITS HAEMOPHILIA CELL THERAPY AND BUY-IN FROM LILLY ON ITS DIABETES PROJECT ARE GOOD SIGNS FOR SIGILON, BUT RESEARCH IS STILL VERY EARLY.

1614
0
Advertisement

Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.

Two weeks ago Vertex spent nearly $1bn on Semma Therapeutics, one of a handful of groups attempting to cure diabetes by implanting patients with shielded islet cells. Sigilon Therapeutics is also active in this area, and is gearing up for its first human trials. 

The company also has cell-based therapies in rare disorders heading towards the clinic. The first human trial of its haemophilia A project should get going before the end of the year, while other efforts focus on factor VII deficiency, Fabry disease and mucopolysaccharidosis I.  

Read More

SOURCEevaluate.com
Previous articleNational Academy of Medicine Launches Global Competition Seeking Solutions for Improving Healthy Longevity
Next articleTmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.